| Abstract
| - Seventeen patients with adult acute leukemia in relapse were treated with aclacinomycin A in 5-day courses given at a dose of 90 to 210 mg/m2/5 days as a daily bolus injection. Complete remission was achieved in patients treated with 130 or more mg/m2/5 days. Three out of seven patients with acute nonlymphocytic leukemia achieved complete remission lasting 15 mo, 14+ mo, and 2 mo. Of seven patients with acute lymphocytic leukemia, one achieved complete remission which lasted more than 11 mo. One patient with refractory anemia with an excess of blast cells also achieved complete remission. Neutropenia and thrombocytopenia occurred in all patients. The dose-limiting factors were gastrointestinal symptoms and stomatitis, the latter occurring in three of the seven patients who received 200-210 mg/m2/5 days. Hyperbilirubinemia associated with antibiotic therapy was seen in four patients. Since aclacinomycin A has significant activity in acute nonlymphocytic leukemia, consideration should be given to exploring its use in combination with other active drugs.
|
